The invention relates to the use of erucic acid (or cis- 13-docosenoic acid, 22:1 n-9) as a pharmaceutical or dietary supplement, to be administered for example in liposomes, for the prevention and treatment of ischemic heart disease, and for the prevention of thrombotic disorders and prothrombotic diathesis in general. The invention also relates to diagnostic methods involving the evaluation of blood concentrations of erucic acid as a diagnostic and prognostic biomarker in cardiovascular diseases and thrombotic disorders.
Treatment and prophylaxis of cardiovascular disorders with erucic acid and related diagnostic methods
Bernardi, Francesco;Baroni, Marcello;Martinelli, Nicola;
2018
Abstract
The invention relates to the use of erucic acid (or cis- 13-docosenoic acid, 22:1 n-9) as a pharmaceutical or dietary supplement, to be administered for example in liposomes, for the prevention and treatment of ischemic heart disease, and for the prevention of thrombotic disorders and prothrombotic diathesis in general. The invention also relates to diagnostic methods involving the evaluation of blood concentrations of erucic acid as a diagnostic and prognostic biomarker in cardiovascular diseases and thrombotic disorders.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
WO_2020065690_A1.pdf
accesso aperto
Descrizione: Testo brevetto EU
Tipologia:
Altro materiale allegato
Licenza:
DRM non definito
Dimensione
2.2 MB
Formato
Adobe PDF
|
2.2 MB | Adobe PDF | Visualizza/Apri |
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
